Singapore-based biopharmaceutical company Travecta Therapeutics said Tuesday it has secured $15 million in its Series A round of financing, led by TKS1, a life science focused venture capital fund formed by life science consulting agency SPRIM and asset management company Tikehau Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
